beta
Trial Radar AI
Clinical Trial NCT07413705 for Depressive Symptoms, Urinary Incontinence, Sexual Dysfunction is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View

BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women 60 International

Recruiting
Clinical Trial NCT07413705 is an interventional study for Depressive Symptoms, Urinary Incontinence, Sexual Dysfunction that is recruiting. It started on November 20, 2025 with plans to enroll 60 participants. Led by BTL Industries Ltd., it is expected to complete by December 11, 2026. The latest data from ClinicalTrials.gov was last updated on February 17, 2026.
Brief Summary
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and sexual function in women who are perimenopausal or postmenopausal without an alternative medical cause before enrollment in the study and are aged 40 years and older. The main question it aims to answer is: Does the combined treatment with EXOMIN...Show More
Detailed Description
This study uses a prospective, multi-center, two-arm, single-blinded, interventional study.

The subjects will be enrolled and randomly assigned to two experimental study arms: the active group (Group A) and the sham group (Group B), in a ratio of 3:1. All enrolled participants will be treated (either active or sham) with both the BTL-699-2 and HPM-6000UF devices. Group A will receive active treatment (BTL-699-2 inte...

Show More
Official Title

Safety and Efficacy of the Combined BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women

Conditions
Depressive SymptomsUrinary IncontinenceSexual Dysfunction
Other Study IDs
  • BTL-699_CTUS400
NCT ID Number
Start Date (Actual)
2025-11-20
Last Update Posted
2026-02-17
Completion Date (Estimated)
2026-12-11
Enrollment (Estimated)
60
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
Depressive Symptoms
Depression
Urinary Incontinence
Sexual Dysfunction
Sexual Function
ExoTMS
Perimenopause
Postmenopause
EMSELLA
EXOMIND
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Single
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalActive treatment with BTL-699-2 and HPM-6000UF
Participants will receive active treatment (BTL-699-2 intensity: up to 70% of MT, HPM-6000UF intensity: up to 100%)
EXOMIND (BTL-699-2) Active Treatment
Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
EMSELLA (HPM-6000UF) ActiveTreatment
Participants will receive six treatments with the HPM-6000UF device delivered to the pelvic floor musculature. The intensity will be adjusted according to the subject's feedback, up to 100%. The treatments will be spaced 3 - 7 days apart.
Sham ComparatorSham treatment with BTL-699-2 and HPM-6000UF
Participants will receive sham treatment (BTL-699-2 intensity: 1% of MT, HPM-6000UF intensity: 1%)
EXOMIND (BTL-699-2) Sham Treatment
Participants will receive six transcranial magnetic stimulation treatments with the BTL-699-2 device over the left dorsolateral prefrontal cortex. The intensity will be set to 1% of the individual's motor threshold. The treatments will be spaced 3 - 7 days apart.
EMSELLA (HPM-6000UF) Sham Treatment
Participants will receive six treatments with the HPM-6000UF device delivered to the pelvic floor musculature. The intensity will be set to 1%. The treatments will be spaced 3 - 7 days apart.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Assessment of Change in Subjective Depressive Symptoms in Perimenopausal and Postmenopausal Women
The change in the score obtained from the self-reported Patient Health Questionnaire-9 (PHQ-9). The baseline score will be compared to the 1-month follow-up score. The total score from this 9-item questionnaire ranges from 0 to 27, with higher scores indicating greater depression severity. Improvement is considered a decrease in the obtained score.
15 months
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Assessment of Change in Objective Symptoms of Depression in Perimenopausal and Postmenopausal Women
The change in the score obtained from the clinician-reported 6-item Hamilton Depression Rating Scale (HAMD-6). The baseline score will be compared to the 1-month follow-up score. The total score ranges from 0 to 22, with higher scores indicating greater depression severity. Improvement is considered a decrease in the obtained score.
15 months
Assessment of Change in Sexual Function in Perimenopausal and Postmenopausal Women
The change in sexual function obtained from the 6-item Female Sex administered at the baseline visit, at the last treatment visit and at both follow-up visits to evaluate the change in sexual function. The total score ranges from 2 to 30, with higher total score indicating better sexual function.
15 months
Assessment of Change in Urinary Incontinence in Perimenopausal and Postmenopausal Women
The change in the score obtained from the self-reported International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF). The total score ranges from 0 to 21, with higher total score indicating greater symptom burden and impact.
15 months
Assessment of Change in Mental Well-Being in Perimenopausal and Postmenopausal Women
The change in the score obtained from the self-reported Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). The minimum scale score is 14 and the maximum is 70. Improvement is considered an increase in the obtained score. The WEMWBS will be filled out at baseline, at the last treatment visit, and at both follow-up visits.
15 months
Assessment of Satisfaction
Subject Satisfaction with treatment outcomes will be assessed using 5-point Likert Scale Subjects Satisfaction Questionnaire. The questionnaire will be administered after the last treatment, at the 1-month and 3-month follow-up visits. Responses to questions about satisfaction with the treatment outcomes will range from "strongly disagree" (1 point) to "strongly agree" (5 points). A higher score for each statement indicate better outcomes.
15 months
Assessment of Therapy Comfort
Therapy Comfort questionnaire will be used for evaluating the comfort during the treatment sessions. The Therapy Comfort questionnaire will be administered after the last treatment. Therapy Comfort questionnaire consists of the question "I found the treatment comfortable", to which responses are based on a 5-point Likert scale (1 = "strongly disagree", and 5 = "strongly agree"). A higher score for the statement "I found the treatment comfortable" indicate higher therapy comfort.
15 months
Assessment of Pain During Therapy
The Therapy Comfort Questionnaire will be used to evaluate pain experienced during the treatment session. It will be administered after the stimulation of each location. The questionnaire includes a 10-point Numeric Analog Scale for pain (0 = no pain, 10 = worst possible pain). Lower scores on the Numeric Analog Scale indicate lower levels of pain.
15 months
Incidence of Treatment-Related Adverse Events
Monitoring of adverse reactions and side effects will be performed for the evaluation of safety of the combined treatment with the BTL-699-2 and HPM-6000UF devices for the improvement of depressive symptoms and sexual function and to identify side effects and adverse events associated with the study treatment.
15 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
40 Years
Eligible Sexes
Female
  • Menopause defined as 12 consecutive months with no menses without an alternative medical cause or perimenopause defined as occurrence of ≥ 60 days of amenorrhea without an alternative medical cause
  • Patient Health Questionnaire-9 (PHQ-9) pre-treatment score of ≥ 5
  • Age ≥ 40 years
  • Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the finger
  • Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime for the improvement of depressive symptoms and/or sexual function, including non-invasive brain stimulation treatments other than the study procedure during study participation
  • Willingness to comply with study instructions and to return to the clinic for the required visits
  • Women of childbearing potential* are required to use birth control measures during the whole duration of the study
  • If applicable, subjects will be maintained on pre-study psychotherapeutic regime, and prescribed chronic medications at a stable therapeutic dosage for at least 1 month prior to study entry *defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.

  • Metallic objects in or near the head
  • rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or within 12 in (30 cm) of the treatment coil*
  • Implanted stimulator devices, implanted defibrillators, implanted neurostimulators
  • Cardiac pacemakers
  • Electronic implants
  • Metal implants
  • rTMS devices are contraindicated for use in patients who have active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, ocular implants and vagus nerve stimulators. - Contraindicated use could result in serious injury or death.
  • Drug pumps
  • Application in the heart area
  • Application of HPM-6000UF in the head area
  • Persons with a tendency to seizure (e.g., persons suffering from hypotonia and epilepsy)
  • Anticoagulation therapy
  • Severe or life-threatening condition
  • Pulmonary insufficiency
  • Heart disorders
  • Renal insufficiency
  • Decompensated** hemorrhagic conditions
  • Decompensated** blood coagulation disorders
  • Decompensated** cardiovascular diseases
  • Malignant tumor or benign tumor
  • Fever
  • Pregnancy

Study specific:

  • Active suicidal intent

  • History of suicide attempts in the last 3 years

  • History or concurrent use of electroconvulsive therapy or vagus nerve stimulation

  • Substance-induced depression or depression secondary to a general medical condition

  • Diagnosis of seasonal affective disorder, psychotic disorder including schizoaffective disorder or current psychotic symptoms, major depression with psychotic features, bipolar disorder

  • Substance abuse

  • Dependence 3 months prior

  • Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia, or movement disorders

  • History of increased intracranial pressure or head trauma

  • Nursing

  • Ongoing intake disorders such as bulimia or anorexia, or intake disorder in the past 12 months

  • Any other disease or condition at the investigator's discretion that may pose risk to the patient or compromise the study

    • Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes. - Failure to follow this restriction could result in serious injury or death. Certain exceptions apply to mouth implants such as standard amalgam dental fillings, single post dental implants, dental bridge work, and braces. If these items are present, the therapy can still be administered.

      • By means of decompensation, it means a patient with a proven medical history of the decompensated health condition and long-term medication. Patients who use certain medications only for preventive purposes, without any proven previous health condition failure are not considered contraindicated.
BTL Industries Ltd. logoBTL Industries Ltd.
No contact data.
3 Study Locations in 2 Countries

Florida

Luxury Psychiatry Clinic, Winter Garden, Florida, 34787, United States
Michelle Dees, MD, Contact, (407) 603-0925, [email protected]
Recruiting

Massachusetts

Aesthetic + Mind MD, Wellesley, Massachusetts, 02481, United States
Omotola Tsarumi, MD, Contact, (617) 668-1239, [email protected]
Recruiting

Ontario

Vitality MD Inc, Toronto, Ontario, M5M3Y8, Canada
Shari Caplan, MD, CCFP, FCFP, ABOIM, Contact, (416) 792-1100, [email protected]
Recruiting